Earnings Summary

Cytek Biosciences Inc’s revenue jumped 20.48% since last year same period to $58.23Mn in the Q4 2023. On a quarterly growth basis, Cytek Biosciences Inc has generated 21.32% jump in its revenue since last 3-months.

Cytek Biosciences Inc’s net profit jumped 55.94% since last year same period to $5.5Mn in the Q4 2023. On a quarterly growth basis, Cytek Biosciences Inc has generated 185.24% jump in its net profits since last 3-months.

Cytek Biosciences Inc’s net profit margin jumped 29.43% since last year same period to 9.45% in the Q4 2023. On a quarterly growth basis, Cytek Biosciences Inc has generated 170.26% jump in its net profit margins since last 3-months.

Cytek Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.04 - a -500% fall from last quarter’s estimates.

Cytek Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.04.

Cytek Biosciences Inc’s earning per share (EPS) fell -29.83% since last year same period to 0.04 in the Q4 2023. This indicates that the Cytek Biosciences Inc has generated -29.83% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cytek Biosciences Inc’s return on assets (ROA) stands at -0.03.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cytek Biosciences Inc’s return on equity (ROE) stands at -0.03.